Latest News

Why Cascades Stock Is Getting Attention Now Cascades (TSX:CAS) is back on investor radars after recent share price moves, with the stock showing mixed short term returns but a stronger trend over the past 3 months and 3 years. See our latest analysis for Cascades. Recent trading has been relatively muted at around CA$13.07. However, the 30 day share price return of 5.9% and 90 day gain of 18.7% suggest momentum has picked up, alongside a 3 year total shareholder return of 62.7% that reflects...

True Potential Investments has appointed Amundi as its exclusive strategic investment solutions partner for its Growth-Aligned fund range, extending the relationship into asset allocation design, index-level fund integration, and technology, while Amundi also recently named Alessia Berardi as head of global macroeconomics. The partnership brings Amundi’s macro research and ALTO platform directly into True Potential’s portfolio construction process, tightening the link between Amundi’s...

CMS has proposed nearly flat Medicare Advantage payment rates for 2027, affecting plans run by NYSE:HUM and peers. Humana is responding with a greater focus on healthcare access efforts, including a new partnership with Carda Health to expand at-home cardiac rehabilitation. The combination of regulatory pressure and care delivery initiatives is drawing attention from investors, patients, and policymakers. Humana, traded as NYSE:HUM, is a major player in Medicare Advantage, so any shift in...

If you are wondering whether BWX Technologies at around US$216.30 is priced for perfection or still offers value, you are not alone. The share price has moved by 3.2% over the last 7 days, 23.3% over the past 30 days, 18.9% year to date and 94.4% over the past year, with a very large 5 year return that is well over 5x. Recent coverage around BWX Technologies has focused on its role in nuclear and defense related projects, as investors watch how these areas shape future contract pipelines and...

If you are wondering whether ATI's recent run still leaves any value on the table, this article will walk through what the current price could be implying about the stock. ATI closed at US$121.72, with a 7 day return of a 2.4% decline, a 30 day return of 4.4%, a year to date return of 2.1% and a 1 year return of 102.1%. This naturally raises questions about what is already priced in. Recent coverage has focused on ATI as investors reassess the company after a very large 5 year return that is...

In January 2026, Glacier Bancorp reported past fourth-quarter 2025 results showing net interest income of US$266.07 million and net income of US$63.78 million, alongside full-year net interest income of US$889.04 million and net income of US$239.03 million. The bank’s results reflected higher net interest income helped by its recent acquisitions, while net charge-offs rose to US$6.4 million in the quarter, including US$2.2 million in deposit overdraft losses. With Glacier Bancorp...

Valley National Bancorp (NasdaqGS:VLY) has appointed Carlos Vazquez as an independent director. Vazquez, a veteran banking executive, will also serve on key board committees. The move adds financial and governance experience to Valley's board at a time of ongoing industry scrutiny. For you as an investor watching NasdaqGS:VLY, this board change sits against a backdrop of a $12.27 share price and a 26.6% return over the past year. Over longer horizons, returns of 17.8% over three years and...

Eva Live, Inc.'s ( NASDAQ:GOAI ) price-to-sales (or "P/S") ratio of 15.3x may look like a poor investment opportunity...

Key Insights The projected fair value for Swisscom is CHF938 based on 2 Stage Free Cash Flow to Equity Swisscom's...

Key Insights The projected fair value for Koninklijke Ahold Delhaize is €62.24 based on 2 Stage Free Cash Flow to...

SkyWest, Inc.'s ( NASDAQ:SKYW ) price-to-earnings (or "P/E") ratio of 9x might make it look like a strong buy right now...

Key Insights Significant control over Melexis by retail investors implies that the general public has more power to...

Integra LifeSciences Holdings Corporation ( NASDAQ:IART ), is not the largest company out there, but it saw significant...

What Pediatrix Medical Group’s recent performance tells investors Pediatrix Medical Group (MD) has drawn fresh attention after recent share moves, with the stock up about 19% over the past 3 months but softer over the month and year to date. That mixed pattern, together with its latest financial profile, is prompting investors to reassess how this newborn and pediatric care provider fits into a diversified healthcare portfolio. See our latest analysis for Pediatrix Medical Group. At a share...

If you are wondering whether SLB is priced fairly right now, the stock's recent moves and current valuation metrics give you quite a bit to think about. The share price closed at US$48.87, with returns of 0.7% over the past week, 28.9% over the past month, 21.6% year to date, 23.1% over one year, and a 5.4% decline over three years, while the five year return stands at 125.0%. Recent coverage has focused on SLB as a key name in the energy sector, with investors paying close attention to how...

Wondering if VEON at US$54.07 is offering value or asking too much? This article walks through what the current price might be implying about the company. The stock has been relatively steady over the last week with a 0.1% decline, while the 1 year return of 19.9% and 3 year return of 260.5% sit alongside a 30 day return of 3.0% and year to date return of 2.6%. Recent news coverage has focused on VEON's position as a telecom operator listed on the Nasdaq and on how investors are interpreting...

Context for NIO (NYSE:NIO) after Recent Price Moves NIO (NYSE:NIO) has drawn fresh attention after recent price swings, with the stock showing a 1% decline over the past day and weaker performance over the past month and past 3 months. For investors tracking electric vehicle makers, these moves raise questions about how NIO’s current share price lines up with its fundamentals, recent financial results, and long term business profile in China and abroad. See our latest analysis for NIO. At a...

American Airlines Group (AAL) has wrapped up FY 2025 with Q4 revenue of US$14.0b and basic EPS of US$0.15, alongside net income of US$99m, putting fresh numbers behind a year where trailing 12 month revenue reached US$54.6b and EPS came in at US$0.17. Over the past few quarters, revenue has ranged from US$12.6b to US$14.4b with EPS swinging between a loss of US$0.72 and a profit of US$0.91, while passenger metrics such as an 82.7% Q4 load factor and revenue yield per available seat kilometer...

Key recent performance snapshot Blackbaud (BLKB) has drawn investor attention after recent trading, with the share price at $54.87 and returns showing a 0.3% move over the past day and a small decline over the past week. The stock has recorded deeper negative returns over the past month, past 3 months, year to date, and past year. This may prompt some investors to reassess how its current valuation lines up with the company’s underlying business profile. See our latest analysis for...

In recent days, commentary around Veeva Systems has emphasized its strong balance sheet, high profitability, and leadership in life sciences cloud software, alongside its role in helping consumer goods companies modernize quality and data systems for AI-readiness. An interesting angle is how Veeva is positioning its QualityOne and unified data platforms as foundational tools for companies seeking to operationalize AI while overcoming legacy system and compliance obstacles. Next, we’ll...

FDA label update puts Afrezza dosing in focus for MannKind (MNKD) investors MannKind (MNKD) shares are reacting to the U.S. Food and Drug Administration’s approval of updated prescribing information for Afrezza, clarifying how adults with diabetes can switch from injectable mealtime insulin or pump boluses to the inhaled product. See our latest analysis for MannKind. The FDA label update lands at a time when MannKind’s latest share price sits at US$5.64, with a 90 day share price return of...

In January 2026, IDEXX Laboratories launched the ImageVue DR50 Plus Digital Imaging System and announced major upgrades to its Cancer Dx Panel and inVue Dx analyzer, advancing AI-powered veterinary imaging and in-clinic cancer diagnostics across North America. By pairing lower-radiation, high-definition imaging with earlier and faster canine cancer detection, IDEXX is deepening its role in integrated veterinary care workflows. Next, we examine how IDEXX’s push into AI-enhanced, lower-dose...

W.W. Grainger (GWW) is back in focus after Oppenheimer shifted its rating to Outperform, citing the company’s growth initiatives, pricing power, and use of artificial intelligence, alongside stronger than expected third quarter results. See our latest analysis for W.W. Grainger. Beyond the rating change, W.W. Grainger’s recent news has included a reaffirmed quarterly cash dividend of $2.26 per share and recognition for profitable growth and strong capital efficiency. Meanwhile, the 90 day...

NxtGen AI Pvt Ltd recently announced it has chosen Dell Technologies’ AI Factory with NVIDIA solutions to provide liquid-cooled PowerEdge servers and scalable infrastructure for what is described as India’s largest dedicated AI factory, aimed at supporting generative AI, agentic AI, physical AI and high-performance computing across enterprises, start-ups and government programs. This collaboration underscores Dell’s growing role as a core infrastructure provider for large-scale AI...